Compare Snap Inc (SNAP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs 10X Genomics Inc — how do they compare? Snap Inc trades at $5.89 (market cap $9.83B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: Snap Inc and 10X Genomics Inc are close in size by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snap Inc for 68 Days and 10X Genomics Inc for 92 Days on average.
| SNAP | TXG | |
|---|---|---|
Market Cap | $9.83B | $10.07B |
Volume | 28,532,342 | 5,657,286 |
Sector | Media | Health |
52-Week High | $9.09 | $97.74 |
52-Week Low | $3.93 | $11.48 |
Typical Hold Time | 68 Days | 92 Days |
Enterprise Value | $11.39B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $5.81, up 0.17% with a bullish technical signal. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M vs -$1.4B in 2022). Recent news highlights AI integration in SPECS glasses with NVIDIA and Salesforce partnerships. Analyst consensus is mixed with 38% buy ratings and $7.78 price target, representing 34% upside potential.
Snap presents a turnaround story with improving financials but remains unprofitable. The stock offers potential upside from AI initiatives and revenue growth, balanced by competitive pressures and regulatory risks. Current valuation at 1.55 P/S appears reasonable for the growth trajectory, though profitability remains the key hurdle for sustained gains.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
